PATENT CLAIM ANALYSIS

Application Number: 16152256
Application Type: Utility
Filing Date: 2018-10
Publication Date: 2019-01
Patent Classification: ["514", "108000"]

Abstract:
Oral dosage forms of osteoclast inhibitors, such as neridronic acid, in an acid form or a salt form, can be used to treat or alleviate pain or related conditions, such as pain associated with complex regional pain syndrome.

Claim (Index 26):
The method of  claim 25 , wherein another prior therapy has failed in the human being.

Metadata:
- Claim Count in Document: 32.0
- Percentile: 97.0
- Lexical Diversity: 1.34375
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['16110869', '15963878', '15703891', '15820305', '15782480']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8667344573864516
- 35 USC 102 Novelty (BERT): 0.5783165555090498
- Combined Prediction Score: 0.8378926671987115
- Mean Citation Score: 639.6442099999998
- Max Citation Score: 670.6982
- Similarity Product: 364.7249591483117

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test